At the 61st ASH Annual Meeting & Exposition, Raajit Rampal, Memorial Sloan Kettering Cancer Center, discusses his presentation: Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care.
1. Given the variable nature of myeloproliferative neoplasms (MPNs), what is the best way of assessing symptom burden? (0:05)
2. How has increased knowledge of the molecular biology of MPNs affected patient management? (0:42)
3. With an increasingly complex treatment regimen, what factors should be considered when selecting and sequencing therapies? (1:55)
4. What novel therapeutic targets are being investigated for MPNs? (3:19)
5. When and how should response assessment be performed? (4:39)
Raajit Rampal has received consultancy fees from Incyte Constellation, Celgene, Blueprint, Stemline, Promedior, Kartos.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Haematology
ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]
Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the current treatment paradigm for large B-cell lymphoma, the limitations of current […]
Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!